Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease - 02/09/11
, Brian G Keevil, MSc a, Ian V Hutchinson, PhD b, Nicholas H Brooks, MD aAbstract |
Purpose |
C-reactive protein is an important risk factor for coronary artery disease, and plasma concentrations are lowered by treatment with pravastatin and aspirin. We examined whether other cardiovascular drugs that are used in the treatment of ischemic heart disease affect C-reactive protein concentrations.
Subjects and methods |
Plasma C-reactive protein concentration was measured by high sensitivity immunonephelometric assay in 333 consecutive patients with stable angina and confirmed coronary artery disease who underwent diagnostic angiography.
Results |
Patients prescribed beta-blockers had significantly lower mean C-reactive protein concentrations than did patients in whom these were not prescribed (by 1.2 mg/L, or 40% difference in geometric mean concentration; P <0.001). This association remained significant (P = 0.03) after excluding patients with contraindications to the use of beta-blockers, and adjusting for the probability of beta-blocker therapy (propensity score) and other clinical predictors of C-reactive protein concentration, including body mass index, high-density lipoprotein cholesterol level, family history of coronary artery disease, and angiographic severity. No differences among types or dosages of beta-blockers were evident.
Conclusion |
Beta-blockers may affect C-reactive protein concentrations. Randomized studies are required to confirm these findings.
Le texte complet de cet article est disponible en PDF.Keywords : Inflammation, C-reactive protein, atherosclerosis, beta-blockers
Plan
Vol 112 - N° 4
P. 269-274 - mars 2002 Retour au numéro
Article précédent
- Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma
- Andrew Wirth, John F Seymour, Rodney J Hicks, Robert Ware, Richard Fisher, Miles Prince, Michael P MacManus, Gail Ryan, Henry Januszewicz, Max Wolf
- Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial
- Iris J Jonkers, Martina F Mohrschladt, Rudi G Westendorp, Arnoud van der Laarse, Augustinus H Smelt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?